Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

Fitness device | Image Credit: © anatolir-stock.adobe.com
Wearable Tech Has Potential to Indicate PAH-Related Decline

April 21st 2025

For this analysis, outcomes were compared between individuals who had pulmonary arterial hypertension (PAH) and healthy controls by using Fitbit-derived data over 12 weeks and then at a 1-year follow-up.

Blood pressure graphic | Image Credit: © Dzianis Vasilyeu-stock.adobe.com
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score

April 8th 2025

PAH | Image Credit: © Richelle-stock.adobe.com
Burden of PAH Weighs Heavy Worldwide

April 4th 2025

Glass pharmaceutical vials | Image credit: ronnarong – stock.adobe.com
Sotatercept Reduces Risk of Death, Transplant, or Hospitalization in Advanced PAH

March 31st 2025

Pulmonary hypertension | Image Credit: © Uladzislau-stock.adobe.com
PAH Therapies Improve Outcomes in PH-ILD

March 26th 2025

More News

An image of the kidneys and the heart
October 24th 2022

Potential Risk Factors Identified for RRT Among Patients With PH

Maggie L. Shaw
According to the study authors, acute decompensated pulmonary hypertension (PH) is often accompanied by systemic congestion and right ventricular flow output, and because PH can be accompanied by acute kidney injury, renal replacement therapy (RRT) may be necessary.
child in bed
October 19th 2022

Syncope May Increase Vasoreactivity Among Pediatric Patients With PAH

Maggie L. Shaw
Although group 1 pulmonary arterial hypertension (PAH) with comorbid syncope has been linked to a poor prognosis among adults, this relationship remains uncertain in pediatric patients, prompting a new study.
Image of septic infection
October 11th 2022

Sepsis, Septic Shock Likely Increase Risk of Adverse Outcomes in PAH

Maggie L. Shaw
Investigators for this study analyzed outcomes among patients hospitalized with pulmonary arterial hypertension (PAH) who have higher risks of adverse health outcomes, in particular sepsis and septic shock.
Image of an ultrasound
October 5th 2022

Optimizing PH-Related Pregnancy Outcomes Requires Additional Risk Stratification

Maggie L. Shaw
This study evaluated pregnancy-related outcomes among women with pulmonary hypertension (PH) ranging from mild to severe in disease severity.
Image of a child on a nebulizer
September 28th 2022

Potential for PHC Necessitates Pediatric Cardiology Care for Children With PAH

Maggie L. Shaw
Outcomes following right heart catheterization in a pediatric patient population were analyzed, with emphasis placed on risk of adverse outcomes following the procedure, especially the development of pulmonary hypertensive crisis (PHC).
Image of different skin tones
September 22nd 2022

Hypertension Manifests Earlier in Black, Hispanic Adults vs White Adults

Maggie L. Shaw
Researchers used 2011-2020 data to examine age- and race-/ethnicity-related trends in hypertension diagnosis, with implications for future cardiovascular disease care.
Group of women
September 16th 2022

Potential for Precision Medicine Approach in PAH Explored in New Study

Maggie L. Shaw
This new study of pulmonary arterial hypertension (PAH) among women examined the in-common symptoms of different disease phenotypes to see where they overlap and ultimately to define the “symptome” according to symptom cluster and characteristics.
Imager of a cardiac alert
September 8th 2022

Mortality Worsens Following Borderline PH Diagnosis Among Patients With LHF

Maggie L. Shaw
Following a recent update to the diagnostic criteria for borderline pulmonary hypertension (PH), which is often associated with left heart failure (LHF), outcomes among patients with both conditions remain uncertain.
Graphic of clinical data
September 1st 2022

Results of Macitentan in PAH From SERAPHIN OL Echo Earlier Trial Safety Data

Maggie L. Shaw
This open-label extension of the SERAPHIN trial evaluated the long-term safety and tolerability of a small daily dose of the endothelin receptor antagonist against pulmonary arterial hypertension (PAH) among patients from the original study.
Image of a pregnant patient
August 26th 2022

Hypertensive Disorders in Pregnancy on the Rise

Maggie L. Shaw
The rates of 3 hypertensive disorders were compared among 2 groups of women: those who gave birth between 1995 and 1999 vs 2015 to 2019.
Doctor with premature infant
August 16th 2022

Risk of PH Increases With Preterm Birth

Maggie L. Shaw
Infants born between the 23rd and 25th weeks of pregnancy, classified as extremely low gestational age newborns, are surviving in increasing numbers, note study authors, and with that is growing clinical interest in their long-term sequelae, including pulmonary hypertension (PH).
Image of pulmonary hypertension
August 12th 2022

Exercise Right Heart Catheterization Can Help Clarify PH Diagnosis

Jared Kaltwasser
Investigators found significant shifts in diagnosis of and prescriptions for pulmonary hypertension (PH) when exercise right heart catheterization was used.
Gary Owens, MD, president, Gary Owens Associates
August 9th 2022

Dr Gary Owens: Payers Need to Be Doing More for Patients With PAH

Gianna Melillo Maggie L. Shaw
Gary Owens, MD, president of Gary Owens Associates, addresses how payers can improve outcomes for persons who have pulmonary arterial hypertension (PAH).
Image of Gary Owens, MD, President, Gary Owens Associates
August 1st 2022

Dr Gary Owens Addresses Managing PAH-Associated Treatment Costs

Gianna Melillo Maggie L. Shaw
Garo Owens, MD, is president of Gary Owens Associates, and here he discusses optimizing treatment goals for patients with pulmonary arterial hypertension (PAH) while reducing care costs.
Man with hand on head
July 28th 2022

How Much Do Physicians Know About SDOH in Their Patients With PAH?

Alisha Lekh
Clinicians interviewed in a recent study reported various social determinants of health (SDOH) affecting health outcomes for patients with pulmonary arterial hypertension (PAH), indicating the need to address SDOH in PAH care.
Neon-enhanced heart image
July 19th 2022

HFpEF-PH Improves Following Treatment With Sacubitril/Valsartan

Maggie L. Shaw
Several measures of hemodynamic capacity were improved in this study that evaluated sacubitril/valsartan use for heart failure with preserved ejection fraction and pulmonary hypertension (HFpEF-PH).
Image of a person deciding on which path to take
July 12th 2022

Functional Capacity Dropped Among Patients With PAH Following COVID-19 Lockdown

Maggie L. Shaw
A Belgian study compared exercise performance before and after COVID-19 lockdown measures were swiftly implemented in the country among patients with preexisting pulmonary arterial hypertension (PAH).
Image of heart and lungs
July 8th 2022

New Findings May Have Implications for PH Classification

Jaime Rosenberg
Researchers have found that patients who have idiopathic pulmonary arterial hypertension (IPAH) with a phenotype characterized by a smoking history and low diffusion capacity for carbon monoxide had little in common with patients with classical IPAH.
white pills lined up
June 29th 2022

Monotherapy May Be Preferred Over Combination Therapy for Specific Patients With PAH

Lindsey Mulrooney
Despite current guidelines recommending combination therapy, there are certain patients with pulmonary arterial hypertension (PAH) who remain on monotherapy for specific reasons.
Image of blood in test tubes
June 23rd 2022

Study Highlights Need for Validated Blood Biomarkers in PAH

Jaime Rosenberg
Collecting more than 3 decades’ worth of data, researchers determined that none of the identified blood biomarkers are accurate enough to take the place of current diagnostic approaches, either due to lack of data or lack of specificity.
Gary Owens, MD
June 5th 2022

Dr Gary Owens Discusses Patient-Centered Care in PAH

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, explains the importance of shared decision making and patient-centered care in pulmonary arterial hypertension (PAH).
Intestinal Microbiota May Potentially Serve as Therapeutic Target in PAH
June 4th 2022

Intestinal Microbiota May Potentially Serve as Therapeutic Target in PAH

Jaime Rosenberg
Gary Owens, MD
May 25th 2022

Dr Gary Owens Describes Treatments in the Pipeline for PAH

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, describes mechanisms, trials of treatments in the works for pulmonary arterial hypertension (PAH).
Site Logo
May 16th 2022

Researchers Highlight Risks of RHC in Pediatric Patients With PAH

Jaime Rosenberg
Based on their findings, the researchers of the retrospective study are calling for close evaluation, careful monitoring, and appropriate treatment to mitigate complications and mortality.
graphic of lungs
May 8th 2022

Novel Therapies Targeting Vasoconstriction and Vascular Remodeling May Improve Outcomes in PAH

Rose McNulty
Drugs currently marketed for pulmonary arterial hypertension have been able to extend the lives of patients but have shown limitations in their ability to prevent or reverse the disease. A novel combination approach may hold promise in future treatments.
Gary Owens, MD
May 2nd 2022

Dr Gary Owens on the Future of PAH Research

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, discusses current treatments available for pulmonary arterial hypertension (PAH) and where future directions in research may lead.
Image of lungs
April 28th 2022

Review: Investigational Therapies Could Transform PAH Treatment

Jared Kaltwasser
A new commentary suggests new pathways might lead to a major shift in the treatment of pulmonary arterial hypertension (PAH).
Gary Owens, MD
April 25th 2022

Dr Gary Owens Explains Opportunities to More Efficiently Identify, Diagnose PAH

Gianna Melillo
Gary Owens, MD, president of Gary Owens Associates, outlines the current epidemiological knowledge of pulmonary arterial hypertension (PAH).
Image of lungs and stethoscope
April 21st 2022

Review Says Therapies Are Boosting Survival From PAH

Jared Kaltwasser
A new review article shows positive trends in survival, as scientists better understand the different types and symptoms of pulmonary arterial hypertension (PAH).
Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study
April 16th 2022

Dapagliflozin Combo Is Not More Effective in Reducing PAH in Preclinical Study

Mary Caffrey
The study used rats with monocrotaline (MCT)-induced PAH to examine whether adding dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, would offer any add-on benefit when used with sildenafil.
<123456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo